Technology

Here at IMMUNE we strive to improve the safety and efficacy of monoclonal antibodies. Becoming a leader in this burgeoning field requires having this improvement in mind while developing both our products and our partnerships. 
NanomAbs Platform

IMMUNE Pharmaceuticals has prioritized the development of Ferritin targeted combo Gemcitabine Paclitaxel NanomAbs. Total ferritin increased and shifted towards acidic (H-rich) ferritin in in the serum of patients with various malignancies such as colon cancer, testicular seminoma, breast cancer, squamous cell carcinoma of the head and neck. In research anti-Ferritin NanomAbs showed marked affinity and improved efficacy for specific tumors such as pancreas and NSCLC. The combination of two drugs induces synergistic anti-tumor effect, while the targeted delivery specifically to tumor cell reduces undesired effects.

 

NanomAb_Structure

NanomAbs comprise four basic modules: 

  1. PEGylated polymeric nanoparticles (PPNs) act as a scaffold which shields the drug from premature elimination or off-target effects.

  2. Proprietary linker molecules embedded within the PPN connect the mAb to the rest of the particle.

  3. Anti-cancer drug (incorporated within the PEGylated polymeric nanoparticles). Several chemotherapeutic drugs with different mechanism of action have been successfully incorporated as lipophilic prodrugs within NanomAbs, e.g. Paclitaxel, Gemcitabine and Oxaliplatin.

  4. Therapeutic mAb mainly functions as a targeting ligand by binding to a specific tumor antigen. Several mAbs have been tested and are being used in NanomAbs products currently developed, including HER2, HER3, EGFR and Ferritin targeting mAbs.